Exodots for diagnostic evaluation and monitoring of alzheimer's disease
Ended Project Grant Awarded Last action
- Award ID
- R43AG080878
- Recipient
-
Wellsim Biomedical Technologies Inc. UEI FD9MPD9K3EC1
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $291,692
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Originally
- Place of performance
- Berkeley, CA 94710, USA
Award details come from USAspending.gov.
Description
- Abstract
- Alzheimer's disease (ad) is the most widespread neurodegenerative disorder. Despite the severity of the disease, early diagnosis of ad is still challenging due to the low accuracy or high cost of neuropsychological tests and neuroimaging. Development of an accurate and cost-effective technology for non-invasive screening and monitoring of ad before irreversible brain damage or mental decline is critical. Wellsim proposes to develop and validate a highly sensitive immunofluorescence assay, termed exodots, for detection and quantification of ad core biomarkers from circulating extracellular vesicles (EV) with high accuracy, high speed, and low cost. This blood-based assay will facilitate minimally invasive assessment of ad patients in primary care settings and continuous monitoring of disease progression.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $291,692 |
Quick answers
Who received award R43AG080878?
R43AG080878 was awarded to Wellsim Biomedical Technologies Inc. by National Institute on Aging (National Institutes of Health) on September 21, 2022.
How much is award R43AG080878 worth?
$291,692 has been obligated on R43AG080878.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award